Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
WHWK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.39 - $3.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)106.08K
Market Cap
$85.30M
Enterprise Value-$48.01M
Total Cash (Recent Filing)$177.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)12.0
Beta0.49
Next Earnings
Nov 05, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding47,128,360
10 Day Avg. Volume148,248
30 Day Avg. Volume106,080
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.56
Enterprise Value/Revenue-2.22
Enterprise Value/Gross Profit9.41
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$2.00Price Target Upside10.50% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityWhitehawk ended with $177.2M in cash, providing an operational runway into 2028.
Pipeline ProgressUpcoming catalysts include IND submissions for key drug candidates, which could lead to further developments.
Strategic DevelopmentsWhitehawk Therapeutics is taking a swift and strategic approach to developing an innovative portfolio of ADCs.
Bears Say
Financial PerformanceWhitehawk recorded a net loss of $0.76 per share vs. the previously estimated net loss of $0.17 per share.
Market RisksRisks include disappointing market uptake of FYARRO and potential medium- to long-term dilution risk.
Operational CostsR&D and SG&A expenses were significantly higher than estimates, indicating increased operational costs.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.39 and its highest was $3.81 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $85.30M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of $0.825 by -$1.585.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 47,128,360 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.76 in its last earnings report, missing expectations of $0.825. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
Whitehawk Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (10.50% Upside)
$2.00 (10.50% Upside)
Blogger Sentiment
Bearish
WHWK Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.42%
12-Months-Change
Fundamentals
Return on Equity
-8.31%
Trailing 12-Months
Asset Growth
77.94%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
WHWK Stock 12 Month Forecast
Average Price Target
$2.00
▲(10.50% Upside)
Technical Analysis
Ownership Overview
26.29% Insiders
2.76% Mutual Funds
4.96% Other Institutional Investors
63.05% Public Companies and
Individual Investors